2nd Quarter - Report
VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOUGLAS STOSS | — |
Medicare/Medicaid MMM
Coverage and Reimbursement of COVID-19 Therapeutics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOUGLAS STOSS | — |
Taxation/Internal Revenue Code TAX
H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOUGLAS STOSS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.